Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of a Single Dose of UB-221 in Healthy Volunteers

NCT04404023 is registered in ClinicalTrials.gov with UBP Greater China (Shanghai) Co., Ltd as lead sponsor.

NCT NCT04404023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04404023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of a Single Dose of UB-221 in Healthy Volunteers
Lead sponsor
UBP Greater China (Shanghai) Co., Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
December 1, 2023
Completion date
June 30, 2025
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria